Proteins of the Bcl-2 family in apoptosis signalling: From mechanistic insights to therapeutic opportunities

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 3, 2004, Pages 119-128

  Chan, Shing Leng ^a   Yu, Victor C ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NONE   (Singapore)

Author keywords

Antisense; Apoptosis; Bcl 2 family; Cancer; Chemical inhibitors; Myocardial infarction; Therapeutic targets

Indexed keywords

2,9 DIMETHOXY 11,12 DIHYDRODIBENZO[C,9] 1,2 DIAZOCINE 5,6 DIOXIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AZOCINE DERIVATIVE; BH1 PROTEIN; BH2 PROTEIN; BH3 PROTEIN; BH4 PROTEIN; BIM PROTEIN; BIMEL PROTEIN; BIML PROTEIN; BIMS PROTEIN; CHELERYTHRINE; CITRININ; COMPLEMENTARY DNA; KU ANTIGEN; OBLIMERSEN; PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN BOK; PROTEIN INHIBITOR; PROTEIN P53; SCAVENGER; UNCLASSIFIED DRUG;

APOPTOSIS; ATHEROSCLEROSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROTECTION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COLORECTAL CANCER; CYTOSKELETON; DEGENERATIVE DISEASE; DEREGULATION; DRUG BIOAVAILABILITY; DRUG COST; FOLLICULAR LYMPHOMA; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; LUNG CANCER; MELANOMA; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MOLECULAR WEIGHT; MYOCARDIAL DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE; PATHOLOGY; PHOSPHORYLATION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SENSOR; SEQUENCE HOMOLOGY; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 1542616703     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.03975.x     Document Type: Short Survey

References (89)

1. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002; 2: 647-56.
2. Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Nat. Immunol. 2003; 4: 410-15.
3. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-2.
4. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-3.
5. Strasser A, Whittingham S, Vaux DL et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl Acad. Sci. USA 1991; 88: 8661-5.
6. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922-33.
7. Li P, Nijhawan D, Budihardjo I et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-89.
8. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
9. Verhagen AM, Ekert PG, Pakusch M et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
10. Okada H, Suh WK, Jin J et al. Generation and characterization of Smac/DIABLO-deficient mice. Mol. Cell Biol. 2002; 22: 3509-17.
11. Susin SA, Lorenzo HK, Zamzami N et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441-6.
12. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001; 412: 95-9.
13. Sattler M, Liang H, Nettesheim D et al. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 1997; 275: 983-6.
14. Huang DC, Strasser A. BH3-only proteins: Essential initiators of apoptotic cell death. Cell 2000; 103: 839-42.
15. Vousden KH. p53: Death star. Cell 2000; 103: 691-4.
16. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001; 7: 683-94.
17. Oda E, Ohki R, Murasawa H et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-8.
18. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 2001; 7: 673-82.
19. Shibue T, Takeda K, Oda E et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 2003; 17: 2233-8.
20. Villunger A, Michalak EM, Coultas L et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and Noxa. Science 2003; 302: 1036-8.
21. Jeffers JR, Parganas E, Lee Y et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4: 321-8.
22. Imaizumi K, Morihara T, Mori Y et al. The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein. J. Biol. Chem. 1999; 274: 7975-81.
23. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev. 1999; 13: 2905-27.
24. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-38.
25. Harada H, Becknell B, Wilm M et al. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol. Cell 1999; 3: 413-22.
26. Datta SR, Katsov A, Hu L et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol. Cell 2000; 6: 41-51.
27. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999; 284: 339-43.
28. Chiang CW, Harris G, Ellig C et al. Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin-3-dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation. Blood 2001; 97: 1289-97.
29. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X (L). Cell 1996; 87: 619-28.
30. O'Connor L, Strasser A, O'Reilly LA et al. Bim: A novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 1998; 17: 384-95.
31. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell 1999; 3: 287-96.
32. Marani M, Tenev T, Hancock D, Downward J, Lemoine NR. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol. Cell Biol. 2002; 22: 3577-89.
33. Bouillet P, Metcalf D, Huang DC et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-8.
34. Bouillet P, Purton JF, Godfrey DI et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002; 415: 922-6.
35. Puthalakath H, Villunger A, O'Reilly LA et al. Bmf: A proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001; 293: 1829-32.
36. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
37. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-90.
38. Tan KO, Tan KM, Yu VC. A novel BH3-like domain in BID is required for intramolecular interaction and autoinhibition of pro-apoptotic activity. J. Biol. Chem. 1999; 274: 23 687-90.
39. Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ. Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 2000; 290: 1761-5.
40. Wei MC, Lindsten T, Mootha VK et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000; 14: 2060-71.
41. Heibein JA, Goping IS, Barry M et al. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J. Exp. Med. 2000; 192: 1391-402.
42. Sutton VR, Davis JE, Cancilla M et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J. Exp. Med. 2000; 192: 1403-14.
43. Stoka V, Turk B, Schendel SL et al. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J. Biol. Chem. 2001; 276: 3149-57.
44. Chen M, He H, Zhan S, Krajewski S, Reed JC, Gottlieb RA. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J. Biol. Chem. 2001; 276: 30 724-8.
45. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003; 115: 61-70.
46. Lindsten T, Ross AJ, King A et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 2000; 6: 1389-99.
47. Cheng EH, Wei MC, Weiler S et al. BCL-2, BCL-X (L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 2001; 8: 705-11.
48. Wei MC, Zong WX, Cheng EH et al. Proapoptotic BAX and BAK. A requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-30.
49. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 2001; 15: 1481-6.
50. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 1997; 139: 1281-92.
51. Kuwana T, Mackey MR, Perkins G et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002; 111: 331-42.
52. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: Coregulation of dimer formation and intracellular localization. Cell 2000; 103: 645-54.
53. Desagher S, Osen-Sand A, Nichols A et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell Biol. 1999; 144: 891-901.
54. Ruffolo SC, Breckenridge DG, Nguyen M et al. BID-dependent and BID-independent pathways for BAX insertion into mitochondria. Cell Death Differ. 2000; 7: 1101-8.
55. Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, Matsuyama S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat. Cell Biol. 2003; 5: 320-9.
56. Guo B, Zhai D, Cabezas E et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003; 423: 456-61.
57. Hashimoto Y, Niikura T, Tajima H et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc. Natl Acad. Sci. USA 2001; 98: 6336-41.
58. Griffiths GJ, Dubrez L, Morgan CP et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J. Cell Biol. 1999; 144: 903-14.
59. Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 2003; 301: 513-17.
60. Muchmore SW, Sattler M, Liang H et al. X-Ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335-41.
61. Petros AM, Medek A, Nettesheim DG et al. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl Acad. Sci. USA 2001; 98: 3012-17.
62. Chittenden T, Flemington C, Houghton AB et al. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 1995; 14: 5589-96.
63. Holinger EP, Chittenden T, Lutz RJ. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem. 1999; 274: 13 298-304.
64. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-92.
65. Schendel SL, Montal M, Reed JC. Bcl-2 family proteins as ion-channels. Cell Death Differ. 1998; 5: 372-80.
66. Hinds MG, Lackmann M, Skea GL, Harrison PJ, Huang DC, Day CL. The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J. 2003; 22: 1497-507.
67. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-64.
68. Zhao ZQ, Morris CD, Budde JM et al. Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion. Cardiovasc. Res. 2003; 59: 132-42.
69. Gill C, Mestril R, Samali A. Losing heart: The role of apoptosis in heart disease. A novel therapeutic target? FASEB J. 2002; 16: 135-46.
70. Guttenplan N, Lee C, Frishman WH. Inhibition of myocardial apoptosis as a therapeutic target in cardiovascular disease prevention: Focus on caspase inhibition. Heart Dis. 2001; 3: 313-18.
71. Sawada M, Hayes P, Matsuyama S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat. Cell Biol. 2003; 5: 352-7.
72. Frankel SR. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: A targeted approach to enhance apoptosis. Semin. Oncol. 2003; 30: 300-4.
73. Jansen B, Wacheck V, Heere-Ress E et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000; 356: 1728-33.
74. Piche A, Grim J, Rancourt C, Gomez-Navarro J, Reed JC, Curiel DT. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res. 1998; 58: 2134-40.
75. Wang JL, Zhang ZJ, Choksi S et al. Cell permeable Bcl-2 binding peptides: A chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000; 60: 1498-502.
76. Chan SL, Lee MC, Tan KO et al. Identification of chelerythrine as an inhibitor of BclXL function. J. Biol. Chem. 2003; 278: 20 453-6.
77. Wang JL, Liu D, Zhang ZJ et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 2000; 97: 7124-9.
78. Enyedy IJ, Ling Y, Nacro K et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 2001; 44: 4313-24.
79. Tzung SP, Kim KM, Basanez G et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat. Cell Biol. 2001; 3: 183-91.
80. Degterev A, Lugovskoy A, Cardone M et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol. 2001; 3: 173-82.
81. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996; 274: 1531-4.
82. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 2000; 166: 29-43.
83. Vila M, Jackson-Lewis V, Vukosavic S et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 2001; 98: 2837-42.
84. Kockx MM, De Meyer GR, Buyssens N, Knaapen MW, Bult H, Herman AG. Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ. Res. 1998; 83: 378-87.
85. Reed JC. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 1999; 17: 2941-53.
86. Rampino N, Yamamoto H, lonov Y et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967-9.
87. Brimmell M, Mendiola R, Mangion J, Packham G. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1998; 16: 1803-12.
88. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc. Natl Acad. Sci. USA 2000; 97: 10 872-7.
89. Kondo S, Shinomura Y, Miyazaki Y et al. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res. 2000; 60: 4328-30.